Exhibit 99.1

                     AutoImmune Inc. 1199 Madia Street Pasadena, CA 91103 Phone: 626-792-1235 Fax: 626-792-1236

Contact:

Robert C. Bishop, Ph.D.

Chairman and Chief Executive Officer

AutoImmune Inc.

626-792-1235

website: http://www.autoimmuneinc.com

FOR IMMEDIATE RELEASE

AUTOIMMUNE INC. REPORTS 2008 THIRD QUARTER FINANCIAL RESULTS

Pasadena, California, November 7, 2008 - AutoImmune Inc. (OTC BB: AIMM.OB) today reported a net loss of $23,000, or break even per share basic and diluted, for the three months ended September 30, 2008, compared with a net loss of $8,000, or break even per share basic and diluted, for the three months ended September 30, 2007. For the nine months ended September 30, 2008, the net loss was $216,000, or $0.01 per share basic and diluted, compared with net loss of $62,000, or break even per share basic and diluted for the same period in 2007. As of September 30, 2008, the Company reported $8.6 million in cash and marketable securities as compared to $8.8 million in cash and marketable securities as of December 31, 2007.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, “Product sales at Colloral LLC during the third quarter were unchanged from the same period prior year.” AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46 “Consolidation of Variable Interest Entities.”

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug, MBP8298, if it reaches the market. In December 2007, BioMS sublicensed its rights in this product to Eli Lilly and Company. During the third quarter just completed, BioMS announced the product was granted fast track designation by the FDA and that it had received a milestone payment from Eli Lilly for successfully passing an interim analysis for safety and futility in its pivotal phase II/III trial of MBP8208 for treatment of secondary progressive multiple sclerosis. We expect the final trial data will be available during the second half of 2009.

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, the Company’s dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in the Company’s most recent Annual Report on Form 10-KSB filed with the Securities and Exchange Commission in the section entitled “Risk Factors.”

- Financial Chart Follows -

AUTOIMMUNE INC.

STATEMENT OF OPERATIONS

(Unaudited)

	Three months ended September 30,						Nine months ended September 30,
	2007			2008			2007			2008
Revenue	$	59,000		$	57,000		$	219,000		$	225,000
Costs and expenses:
Cost of revenue		9,000			1,000			20,000			29,000
Research and development		7,000			3,000			95,000			93,000
Selling, general and administrative		163,000			125,000			532,000			511,000
Total costs and expenses		179,000			129,000			647,000			633,000
Interest income		112,000			51,000			335,000			195,000
Minority interest in joint venture		—			(2,000	)		6,000			(3,000	)
Other income		—			—			25,000			0
		112,000			49,000			366,000			192,000
Net loss	$	(8,000	)	$	(23,000	)	$	(62,000	)	$	(216,000	)
Net loss per share - basic	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.01	)
Net loss per share - diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.01	)
Weighted average common shares outstanding - basic		16,979,623			16,999,623			16,967,504			16,998,820
Weighted average common shares outstanding - diluted		16,979,623			16,999,623			16,967,504			16,998,820

CONDENSED BALANCE SHEET

(Unaudited)

	December 31, 2007		September 30, 2008
Cash and marketable securities	$	8,804,000	$	8,591,000
Other current assets		167,000		154,000
Total assets	$	8,971,000	$	8,745,000
Current liabilities	$	128,000	$	129,000
Minority interest in joint venture		11,000		24,000
Total stockholders’ equity		8,832,000		8,592,000
Total liabilities and equity	$	8,971,000	$	8,745,000